Assuring manufacturing and data integrity for cell and gene therapy regulatory compliance
Sponsor
Data integrity has become a major challenge to the pharmaceutical industry as equipment becomes increasingly computerized. Data is no longer represented by a simple printout or a value on the screen; instead it consists of many parameters and calculations and can, in some cases, even be re-processed to display result differently. All the data we create during product manufacturing and analysis must maintain its integrity and follow ALCOA plus principles throughout the life cycle of the product. Reliable data is key in guaranteeing that products are safe for patients. To ensure this, computerized systems are used to generate data and are these systems must undergo validation to demonstrate they are fit for purpose.
Computerized Systems Validation (CSV) consists of documented evidence that a computerized system adheres to ALCOA plus principles. Ensuring this adherence to through technical controls is challenging and often quite complex and time-consuming. The requirements to meet ALCOA plus come from 21 CFR Part 11 (FDA) and Eudralex GMP Annex 11 (EU), and apply to all computerized systems. As these are interpreted by the manufacturers of such computerized systems and translated into technical capabilities built into the systems, differences in the capability of meeting these principles inevitably arise, which carries challenges for the companies using them in GMP settings.
- How to bring regulatory requirements for computerized systems and data integrity into practice.
- How to ensure data integrity when using computerized systems.
- Technical challenges and solutions when using computerized systems in the field of CGT
SPEAKERS
You might also like
Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products
Considerations to optimize and act upon long-term follow-up studies for cell and gene therapies
Discover the road to success for viral vector production: strategies, insights, and regulatory considerations
Case study: becoming the first GMP-certified cell and gene therapy manufacturing facility in Thailand
